Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial
Aurore Perrot, Thierry Facon, Torben Plesner, Saad Z Usmani, Shaji Kumar, Nizar J Bahlis, Cyrille Hulin, Robert Z Orlowski, Hareth Nahi, Peter Mollee, Karthik Ramasamy, Murielle Roussel, Arnaud Jaccard, Michel Delforge, Lionel Karlin, Bertrand Arnulf, Ajai Chari, Jianming He, Kai Fai Ho, Rian Van Rampelbergh, Clarissa M Uhlar, Jianping Wang, Rachel Kobos, Katharine S Gries, John Fastenau, Katja Weisel, Aurore Perrot, Thierry Facon, Torben Plesner, Saad Z Usmani, Shaji Kumar, Nizar J Bahlis, Cyrille Hulin, Robert Z Orlowski, Hareth Nahi, Peter Mollee, Karthik Ramasamy, Murielle Roussel, Arnaud Jaccard, Michel Delforge, Lionel Karlin, Bertrand Arnulf, Ajai Chari, Jianming He, Kai Fai Ho, Rian Van Rampelbergh, Clarissa M Uhlar, Jianping Wang, Rachel Kobos, Katharine S Gries, John Fastenau, Katja Weisel
Abstract
Purpose: To evaluate the effects of daratumumab, lenalidomide, and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) on patient-reported outcomes (PROs) in the phase III MAIA study.
Patients and methods: PROs were assessed on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item and the EuroQol 5-dimensional descriptive system at baseline and every 3 months during treatment. By mixed-effects model, changes from baseline are presented as least squares means with 95% CIs.
Results: A total of 737 transplant-ineligible (TIE) patients with newly diagnosed multiple myeloma were randomly assigned to D-Rd (n = 368) or Rd (n = 369). Compliance with PRO assessments was high at baseline (> 90%) through month 12 (> 78%) for both groups. European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item global health status scores improved from baseline in both groups and were consistently greater with D-Rd at all time points. A global health status benefit was achieved with D-Rd, regardless of age (< 75 and ≥ 75 years), baseline Eastern Cooperative Oncology Group (ECOG) performance status score, or depth of response. D-Rd treatment resulted in significantly greater reduction in pain scores as early as cycle 3 (P = .0007 v Rd); the magnitude of change was sustained through cycle 12. Reductions in pain with D-Rd were clinically meaningful in patients regardless of age, ECOG status, or depth of response. Similarly, PRO improvements were observed with D-Rd and Rd on the EuroQol 5-dimensional descriptive system visual analog scale score.
Conclusion: D-Rd compared with Rd was associated with faster and sustained clinically meaningful improvements in PROs, including pain, in transplant-ineligible patients with newly diagnosed multiple myeloma regardless of age, baseline ECOG status, or depth of treatment response.
Trial registration: ClinicalTrials.gov NCT02252172.
Figures
References
- Moreau P, Attal M, Facon T: Frontline therapy of multiple myeloma. Blood 125:3076-3084, 2015
- Moreau P San Miguel J Sonneveld P, et al. : Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:iv52-iv61, 2017
- Kumar SK Callander NS Alsina M, et al. : NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018. J Natl Compr Canc Netw 16:11-20, 2018
- Benboubker L Dimopoulos MA Dispenzieri A, et al. : Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med 371:906-917, 2014
- Mateos MV Richardson PG Schlag R, et al. : Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: Updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 28:2259-2266, 2010
- San Miguel JF Schlag R Khuageva NK, et al. : Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359:906-917, 2008
- de Weers M Tai YT van der Veer MS, et al. : Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 186:1840-1848, 2011
- Overdijk MB Verploegen S Bogels M, et al. : Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs 7:311-321, 2015
- Overdijk MB Jansen JH Nederend M, et al. : The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcgamma receptor-mediated cross-linking. J Immunol 197:807-813, 2016
- Krejcik J Casneuf T Nijhof IS, et al. : Daratumumab depletes CD38+ immune-regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood 128:384-394, 2016
- van de Donk NWCJ Janmaat ML Mutis T, et al. : Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunol Rev 270:95-112, 2016
- DARZALEX® (daratumumab) injection, for intravenous use [packet insert]. Horsham, PA, Janssen Biotech, 2019
- Adams HC III Stevenaert F Krejcik J, et al. : High-parameter mass cytometry evaluation of relapsed/refractory multiple myeloma patients treated with daratumumab demonstrates immune modulation as a novel mechanism of action. Cytometry A 95:279-289, 2019
- Mateos MV Dimopoulos MA Cavo M, et al. : Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med 378:518-528, 2018
- Facon T Kumar S Plesner T, et al. : Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. N Engl J Med 380:2104-2115, 2019
- Seitzler S Finley-Oliver E Simonelli C, et al. : Quality of life in multiple myeloma: Considerations and recommendations. Expert Rev Hematol 12:419-424, 2019
- Wisloff F Eika S Hippe E, et al. : Measurement of health-related quality of life in multiple myeloma. Nordic Myeloma Study Group. Br J Haematol 92:604-613, 1996
- Wisloff F, Hjorth M: Health-related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma. Nordic Myeloma Study Group. Br J Haematol 97:29-37, 1997
- Herdman M Gudex C Lloyd A, et al. : Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 20:1727-1736, 2011
- Devlin NJ Shah KK Feng Y, et al. : Valuing health-related quality of life: An EQ-5D-5L value set for England. Health Econ 27:7-22, 2018
- Kvam AK, Fayers PM, Wisloff F: Responsiveness and minimal important score differences in quality-of-life questionnaires: A comparison of the EORTC QLQ-C30 cancer-specific questionnaire to the generic utility questionnaires EQ-5D and 15D in patients with multiple myeloma. Eur J Haematol 87:330-337, 2011
- Pickard AS, Neary MP, Cella D: Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes 5:70, 2007
- Baz R Lin HM Hui AM, et al. : Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life. Support Care Cancer 23:2789-2797, 2015
- Usmani SZ Facon T Kumar S, et al. : Impact of age on efficacy and safety of daratumumab in combination with lenalidomide and dexamethasone (D-Rd) in patients (pts) with transplant-ineligible newly diagnosed multiple myeloma (NDMM): MAIA. J Clin Oncol 37:8035, 2019
- Gauthier LR Dworkin RH Warr D, et al. : Age-related patterns in cancer pain and its psychosocial impact: Investigating the role of variability in physical and mental health quality of life. Pain Med 19:658-676, 2018
- Balducci L, Dolan D, Hoffe SA: Palliative care in older patients with cancer. Cancer Control 22:480-488, 2015
- Ramsenthaler C Kane P Gao W, et al. : Prevalence of symptoms in patients with multiple myeloma: A systematic review and meta-analysis. Eur J Haematol 97:416-429, 2016
- Torres LM Revnic J Knight AD, et al. : Relationship between onset of pain relief and patient satisfaction with fentanyl pectin nasal spray for breakthrough pain in cancer. J Palliat Med 17:1150-1157, 2014
- Rifkin RM Bell JA DasMahapatra P, et al. : Treatment satisfaction and burden of illness in patients with newly diagnosed multiple myeloma. Pharmacoecon Open 4:473-483, 2019
- Ramsenthaler C Osborne TR Gao W, et al. : The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: A multi-centre study. BMC Cancer 16:427, 2016
- Chari A Romanus D DasMahapatra P, et al. : Patient-reported factors in treatment satisfaction in patients with relapsed/refractory multiple myeloma (RRMM). Oncologist 24:1479-1487, 2019
- Delforge M Dhawan R Robinson D Jr, et al. : Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: Results from the VISTA trial. Eur J Haematol 89:16-27, 2012
- Dimopoulos MA Palumbo A Hajek R, et al. : Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged >/= 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: Results of a randomized trial. Leuk Lymphoma 55:1489-1497, 2014
- Dimopoulos MA Weisel KC Song KW, et al. : Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. Haematologica 100:1327-1333, 2015
- Gries K Fastenau J Chen Y, et al. : Health-related quality of life in patients with newly diagnosed multiple myeloma who are ineligible for stem cell transplantation: Results from the ALCYONE trial. J Clin Oncol 36:8042, 2018
Source: PubMed